TriSalus Expands PEDD Portfolio with FDA-Cleared TriNav Advance for Liver Embolization
Event summary
- TriSalus Life Sciences received FDA 510(k) clearance for TriNav® Advance on September 22, 2026.
- TriNav® Advance expands the company's Pressure-Enabled Drug Delivery™ (PEDD) portfolio, enabling access to small, distal vessels via compatible microcatheters.
- The device can be used in two configurations: telescoping for selective delivery to smaller vessels and high-flow for easy infusion through a large lumen.
- TriSalus plans to initiate a limited market release of TriNav Advance in the coming weeks.
The big picture
TriSalus Life Sciences is strengthening its position in the oncology medical technology space with the FDA clearance of TriNav Advance. This expansion of its PEDD portfolio aligns with broader industry trends towards more targeted and flexible drug delivery solutions. The clearance supports TriSalus' strategy of integrating novel delivery technology with standard-of-care therapies, potentially enhancing its competitive edge in the treatment of solid tumors.
What we're watching
- Adoption Dynamics
- How the flexibility of TriNav Advance will affect its adoption across a broader range of liver embolization procedures.
- Market Expansion
- Whether TriSalus can leverage this clearance to expand its impact in cases involving tortuous anatomies beyond the liver.
- Competitive Positioning
- The pace at which TriSalus can differentiate itself in the competitive landscape of liver-directed therapies.
Related topics